Poseida Therapeutics (Poseida Therapeutics) EPS Growth Rate (Future 3Y To 5Y Estimate) : N/A (As of Jun. 09, 2024)

View and export this data going back to 2020. Start your Free Trial

What is Poseida Therapeutics EPS Growth Rate (Future 3Y To 5Y Estimate)?

EPS Growth Rate (Future 3Y To 5Y Estimate) is the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

As of today, Poseida Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) is N/A.

Competitive Comparison of Poseida Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate)

For the Biotechnology subindustry, Poseida Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate), along with its competitors' market caps and EPS Growth Rate (Future 3Y To 5Y Estimate) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Poseida Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Poseida Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) distribution charts can be found below:

* The bar in red indicates where Poseida Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) falls into.

Poseida Therapeutics (NAS:PSTX) EPS Growth Rate (Future 3Y To 5Y Estimate) Explanation

EPS Growth Rate (Future 3Y To 5Y Estimate) s the average growth rate of earnings per share (EPS) estimates over a 3-year to 5-year period.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average earnings per share (EPS) estimates growth rate.

Poseida Therapeutics EPS Growth Rate (Future 3Y To 5Y Estimate) Related Terms

Thank you for viewing the detailed overview of Poseida Therapeutics's EPS Growth Rate (Future 3Y To 5Y Estimate) provided by GuruFocus.com. Please click on the following links to see related term pages.

Poseida Therapeutics (Poseida Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Poseida Therapeutics Inc (NAS:PSTX) » Definitions » EPS Growth Rate (Future 3Y To 5Y Estimate)

Comparable Companies

Traded in Other Exchanges

2RZ:Germany

Address

9390 Towne Centre Drive, Suite 200, San Diego, CA, USA, 92121

Website

https://www.poseida.com

Poseida Therapeutics Inc is a clinical-stage biopharmaceutical company focused on leveraging non-viral gene engineering technologies to create life-saving therapeutics for patients with a high unmet medical need. It has built a pipeline of autologous and allogeneic chimeric antigen receptor T cell, or CAR-T, product candidates, initially focused on the treatment of hematological malignancies and solid tumours.

Executives

John P. Schmid	director	6310 NANCY RIDGE DRIVE, SUITE 101, SAN DIEGO CA 92121
Luke Corning	director	614 DAVIS STREET, EVANSTON IL 60201
Marcea Bland Lloyd	director	9360 TOWNE CENTRE DRIVE, SUITE 110, SAN DIEGO CA 92121
Charles M Baum	director	C/O MIRATI THERAPEUTICS INC., 9393 TOWNE CENTRE DRIVE, STE 200, SAN DIEGO CA 92121
Cynthia Collins	director	65 WEST WATKINS MILL ROAD, GAITHERSBURG MD 20878
Rafael Amado	director	210 EAST GRAND AVE, SOUTH SAN FRANCISCO CA 94080
Kristin Yarema	officer: President, Cell Therapy	C/O ATARA BIOTHERAPEUTICS, INC., 611 GATEWAY BLVD., SUITE 900, SOUTH SAN FRANCISCO CA 94080
Malin Life Sciences Holdings Ltd	10 percent owner	2 HARBOUR SQUARE, CROFTON ROAD, DUN LAOGHAIRE, CO, DUBLIN L2 ----
Eric Ostertag	director, 10 percent owner, officer: Chief Executive Officer	C/O POSEIDA THERAPEUTICS, INC., 4242 CAMPUS POINT COURT, SUITE 700, SAN DIEGO CA 92121
Kerry D. Ingalls	officer: Chief Operating Officer	C/O POSEIDA THERAPEUTICS, INC., 9390 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121
Brent Warner	officer: President, Gene Therapy	C/O POSEIDA THERAPEUTICS, INC., 9390 TOWNE CENTRE DRIVE, SUITE 200, SAN DIEGO CA 92121
Matthew A. Spear	officer: Chief Medical Officer	C/O POSEIDA THERAPEUTICS, INC., 4242 CAMPUS POINT COURT, SUITE 700, SAN DIEGO CA 92121
Harry J Leonhardt	officer: GC & Chief Compliance Officer	C/O HALOZYME THERAPEUTICS, INC., 11388 SORRENTO VALLEY BLVD., SAN DIEGO CA 92121
David Hirsch	director	C/O LONGITUDE CAPITAL PARTNERS, LLC, 800 EL CAMINO REAL, SUITE 220, MENLO PARK CA 94025
Sean Murphy	director, 10 percent owner	C/O NOVAN, INC., 4222 EMPEROR BOULEVAND, SUITE 200, DURHAM NC 27703